Northwest Biotherapeutics, Inc.
General ticker "NWBO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $353.6M (TTM average)
Northwest Biotherapeutics, Inc. does not follow the US Stock Market performance with the rate: -17.4%.
Estimated limits based on current volatility of 3.5%: low 0.23$, high 0.24$
Factors to consider:
- Total employees count: 22 as of 2022
- Top business risk factors: Insufficient funding, Reimbursement risks, Labor/talent shortage/retention, Manufacturing risks, Market viability
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.18$, 0.50$]
- 2025-12-31 to 2026-12-31 estimated range: [0.15$, 0.43$]
Financial Metrics affecting the NWBO estimates:
- Positive: with PPE of -3.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.30 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 2.36 <= 3.41
Short-term NWBO quotes
Long-term NWBO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.68MM | $1.93MM | $1.38MM |
| Operating Expenses | $68.86MM | $57.44MM | $67.89MM |
| Operating Income | $-67.18MM | $-55.51MM | $-66.51MM |
| Non-Operating Income | $-37.85MM | $-7.09MM | $-17.27MM |
| Interest Expense | $6.07MM | $5.24MM | $7.77MM |
| R&D Expense | $35.51MM | $27.73MM | $34.89MM |
| Income(Loss) | $-105.03MM | $-62.60MM | $-83.78MM |
| Profit(Loss)* | $-105.03MM | $-62.60MM | $-83.78MM |
| Stockholders Equity | $-128.10MM | $-65.77MM | $-78.98MM |
| Assets | $31.32MM | $27.86MM | $26.73MM |
| Operating Cash Flow | $-52.77MM | $-53.64MM | $-57.02MM |
| Capital expenditure | $2.90MM | $3.44MM | $1.01MM |
| Investing Cash Flow | $-2.90MM | $-3.44MM | $-1.01MM |
| Financing Cash Flow | $41.97MM | $52.76MM | $56.78MM |
| Earnings Per Share** | $-0.10 | $-0.06 | $-0.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.